No relief to Neon labs to discontinuation of Local Anesthetic Lidocain
Advertisement
In a setback to Neon Laboratories, the National Pharmaceutical Pricing Authority (NPPA) has rejected the drug maker's plea to discontinue scheduled formulation Lox 5% Ointment (Lidocaine 5%).
This came in response to the form-IV intimation received from Neon Laboratories Limited for discontinuation of scheduled formulation viz., Lox 5% Ointment (Lidocaine 5%) under Para 21(2) of DPCO, 2013.
For more details, check out the full story on the link below:
Setback: NPPA Panel Rejects Neon Labs Plea To Discontinue Local Anesthetic Lidocaine
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.